title: PI3K-δ inhibitor produces long-lasting responses.
abstract: In a phase I study, Gilead Sciences' PI3K-δ inhibitor idelalisib produced rapid tumor shrinkage-a response that lasted for 17 months on average-in about half of the 54 patients with chronic lymphocytic leukemia who participated.
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D018572:Disease-Free Survival; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011687:Purines / Q000008:administration & dosage* / Q000009:adverse effects; D052999:Quinazolinones / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011687:Purines; D052999:Quinazolinones; C552946:idelalisib